There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM – Research Report), Dyne Therapeutics (DYN – Research Report) and Dexcom (DXCM – Research Report) with bullish sentiments.
Immunome (IMNM)
In a report released today, Brian Cheng from J.P. Morgan initiated coverage with a Buy rating on Immunome and a price target of $24.00. The company’s shares closed last Monday at $13.82.
According to TipRanks.com, Cheng ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $32.50, a 137.1% upside from current levels. In a report issued on April 15, Guggenheim also initiated coverage with a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Dexcom (DXCM)
In a report issued on April 25, Mike Kratky from Leerink Partners maintained a Buy rating on Dexcom, with a price target of $161.00. The company’s shares closed last Monday at $125.81.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $155.31, implying a 24.1% upside from current levels. In a report issued on April 10, UBS also maintained a Buy rating on the stock with a $163.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMNM:
